Compare JHG & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHG | CRL |
|---|---|---|
| Founded | 1934 | 1947 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.5B |
| IPO Year | 2003 | 1999 |
| Metric | JHG | CRL |
|---|---|---|
| Price | $51.41 | $165.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $47.38 | ★ $197.58 |
| AVG Volume (30 Days) | ★ 3.6M | 754.3K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 104.30 | N/A |
| EPS | ★ 5.23 | N/A |
| Revenue | $1,743,700,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | $6.18 | $3.26 |
| P/E Ratio | $9.82 | ★ N/A |
| Revenue Growth | ★ 74.39 | 10.48 |
| 52 Week Low | $28.26 | $91.86 |
| 52 Week High | $53.76 | $228.88 |
| Indicator | JHG | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 47.93 |
| Support Level | $50.02 | $146.49 |
| Resistance Level | $53.76 | $166.62 |
| Average True Range (ATR) | 0.63 | 6.68 |
| MACD | -0.06 | 1.45 |
| Stochastic Oscillator | 55.67 | 54.04 |
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.